Eli Lilly raises 2026 revenue guidance on Mounjaro demand

Eli Lilly Raises 2026 Revenue Guidance on Mounjaro Demand

Eli Lilly's latest quarter showed stronger-than-expected Mounjaro demand, prompting a higher 2026 revenue outlook. The update matters for analysts and BD teams tracking obesity-market momentum, trial catalysts, and next earnings milestones.

IntelligenceRegulatory Impact▾

EMA decisions frame this story. Regulatory relevance is medium for obesity, with Mounjaro most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

Key Takeaways

• Eli Lilly raised full-year 2026 revenue guidance by $2 billion following Q1 results that exceeded internal expectations.
• Mounjaro worldwide revenue reached $8.7 billion in Q1 2026, up 125% year over year, with U.S. sales of $4.2 billion, an increase of 59%.
• Tirzepatide trials are underway in atrial fibrillation and heart failure with preserved ejection fraction (HFpEF), preoperative bariatric surgery optimization, post-bariatric surgery GLP-1 use, type 1 diabetes, and opioid use disorder.
• Multiple tirzepatide studies remain in recruitment or pre-recruitment phases, offering future data points for analyst model updates.

IntelligenceCompetitive Intelligence▾

Competitive pressure is high. Eli Lilly reshape positioning, formulary leverage, and partnership options. Benchmark pipeline differentiation and regional market access assumptions against this development.

Q1 2026 Results Drove the Guidance Increase

Eli Lilly raised full-year 2026 revenue guidance by $2 billion following Q1 performance. The driver was clear: worldwide Mounjaro revenue increased 125% to $8.7 billion in Q1 2026. Within that, U.S. revenue was $4.2 billion, an increase of 59%.

For analysts and business development teams, this update signals management's confidence in sustained Mounjaro demand through 2026. The guidance revision reflects Q1 results that exceeded prior internal expectations and supports model updates incorporating the higher full-year revenue baseline.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance medium for obesity. Expect implications for pricing, access, and launch sequencing.

Mounjaro's Approved Indication and Mechanism

Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. The drug is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist.

The dual receptor mechanism—combining GIP and GLP-1 signaling—distinguishes tirzepatide from single-receptor GLP-1 agonists. While the FDA label specifies type 2 diabetes, the compound is under investigation in several other clinical settings, as documented in active and planned trials.

IntelligenceStrategic Takeaways▾

Eli Lilly raised full-year 2026 revenue guidance by $2 billion following Q1 results that exceeded internal expectations. Mounjaro worldwide revenue reached $8.7 billion in Q1 2026, up 125% year over year, with U.S. sales of $4.2 billion, an increase of 59%. Tirzepatide trials are underway in atrial fibrillation and heart failure with preserved ejection fraction (HFpEF), preoperative bariatric surgery optimization, po

Tirzepatide Clinical Development Pipeline

Beyond the approved diabetes indication, researchers are investigating tirzepatide across multiple therapeutic areas. A phase 4 trial (NCT07630454) evaluates tirzepatide on atrial fibrillation recurrence after catheter ablation in patients with obesity and heart failure with preserved ejection fraction (HFpEF), with enrollment not yet underway. A separate study (NCT07622992) examines preoperative optimization with tirzepatide, ketogenic diet, or standard care before one anastomosis gastric bypass surgery, also in the pre-recruitment phase.

In metabolic and endocrine indications, a recruiting phase 2/3 trial (NCT07284511) is investigating tirzepatide in adults with type 1 diabetes. A phase 2/3 study (NCT06162715) is enrolling by invitation to assess GLP-1 receptor agonists post-bariatric surgery through the GRABS pilot trial at Vanderbilt University Medical Center. Additionally, a recruiting phase 2 trial (NCT06651177) evaluates tirzepatide as an adjunct to buprenorphine for opioid use disorder.

IntelligenceEvidence Quality▾

Grounded in 1 regulatory source.

Market Momentum and Competitive Positioning

The $8.7 billion worldwide quarterly Mounjaro revenue and 125% year-over-year growth establish a significant reference point for competitive benchmarking in the GLP-1 and obesity markets. For BD teams modeling peer performance and market share dynamics, Lilly's Q1 2026 results and elevated guidance provide updated data for assessing market demand and adoption trajectories through fiscal 2026.

What to Watch Next

Analysts and BD teams should track enrollment progress and clinical readouts from the tirzepatide trials listed above. Eli Lilly's next earnings presentation and financial calendar disclosures will provide updated Mounjaro revenue trends and any forward guidance adjustments. Model updates should incorporate the higher 2026 revenue baseline disclosed in this guidance revision, and teams should compare subsequent quarterly revenue mix and guidance language against this Q1 reset.

Frequently Asked Questions

Related profiles

• MOUNJARO

Related coverage

• FDA Issues June 2026 Guidance: Gene Therapy, Payor Comms, and CMC Flexibilities
• Eli Lilly's donanemab wins FDA approval for early Alzheimer's disease
• Johnson And Johnson ASCO 2026 Data Adds Depth To JNJ Valuation Story